logo
As health benefit costs continue to surge, Mercer's research reveals that employers face tough decisions regarding their 2026 benefit offerings

As health benefit costs continue to surge, Mercer's research reveals that employers face tough decisions regarding their 2026 benefit offerings

Business Wire7 days ago
NEW YORK--(BUSINESS WIRE)-- Mercer, a business of Marsh McLennan (NYSE: MMC) and a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people, today released its Survey on Health and Benefit Strategies for 2026. According to the survey, more employers will likely reduce benefits in 2026 as they try to control fast-growing health benefit costs.
In recent years, the tight labor market and concerns about healthcare affordability have made employers reluctant to reduce the value of health benefits by raising deductibles or making other changes that shift more responsibility for healthcare cost to employees. But this year, more employers seem likely to use this tactic to slow health plan cost growth. Half (51%) of large employers (those with 500 or more employees) say they are likely or very likely to make plan design changes in 2026 that would shift more cost to employees, such as raising deductibles or out-of-pocket maximums. That's up from 45% in last year's survey.
'Employers project average health benefit costs to grow by nearly 6% this year, and 2026 may be even more challenging from a cost perspective,' said Ed Lehman, Mercer's US Health & Benefits Leader. 'While short-term cost containment actions might be needed to address current budget realities, we also see some employers using longer-term strategies, such as offering narrow network plans, that emphasize high-quality, high-value care. These strategies may improve health outcomes or make healthcare more affordable for employees."
Some employers will pursue other strategies to slow cost growth. According to the survey, 35% of large employers will offer a non-traditional medical plan option in 2026 that seeks to provide employees with higher-quality, more cost-efficient care. Employers offer these alternative plans to provide choices to employees with a range of medical and financial needs. Variable copay plans are one example and typically offer no or low deductibles and set copayments for services based on individual providers' fees. These copays are fixed and communicated up front, giving members the opportunity to select lower-cost providers.
The survey found that among the 6% of large employers currently offering a variable copay plan, 28% of their covered employees, on average, chose to enroll in them in 2025.
Weight-loss medication cost is a top concern
Sharp growth in the utilization of glucagon-like peptide 1 (GLP-1) drugs for the treatment of diabetes and obesity is having a significant impact on prescription drug benefit costs. While employers have long covered GLP-1 drugs for diabetes, fewer than half (44%) of large employers cover the drugs specifically approved to treat obesity. Given the high cost of these drugs (about $1,000 per month per patient, not counting manufacturers' rebates, which vary), and the large number of plan members that could potentially benefit from them, managing this cost is by far the top priority in pharmacy benefits among survey respondents, with 77% saying it is extremely or very important.
'While the trend over the past couple of years has been to add coverage for GLP-1s approved for weight-loss, some employers facing large cost increases in 2026 may feel this coverage is out of reach,' says Alysha Fluno, Mercer's Pharmacy Innovation Leader. 'Employers are weighing the immediate costs of covering these drugs against the potential for generating savings down the road once their workforce's health improves.'
More broadly, some employers are evaluating new approaches to providing and managing the costs of pharmacy benefits. Well over half of large employers (61%) are now actively exploring some type of alternative to standard pharmacy benefit contracts that would potentially provide greater clarity about the cost of drugs or specific services offered by pharmacy benefit managers.
Well-being and mental health continue to be a priority
Employers remain committed to helping employees manage stress and build coping skills, which may help prevent the onset of more serious mental health issues. More than 75% of large employers will offer digital stress management or resiliency resources in 2026, such as mindfulness and meditation apps, or apps grounded in cognitive behavioral therapy. Half (51%) will offer in-person or live online resources for stress management and resiliency, such as individual or group training sessions or coaching.
Employers are also providing training for managers on how to recognize employees who are struggling with their mental health, offer support and direct them to resources. This type of training is increasingly recognized as a strategy for fostering a healthy workplace. Nearly 40% of all large employers surveyed – and 60% of those with 20,000 or more employees – conduct mental health training for managers. These efforts may be a response to a growing need. According to Mercer's research, nearly half (45%) of US employees feel stressed most days at work.
About Mercer's Survey on Health and Benefit Strategies for 2026
This study includes 711 US-based organizations (504 organizations with 500 or more employees and 207 organizations with fewer than 500 employees). The study was fielded between April 8 and April 25, 2025. Click here to learn more.
About Mercer
Mercer, a business of Marsh McLennan (NYSE: MMC), is a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people. Marsh McLennan is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of over $24 billion and more than 90,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit mercer.com, or follow on LinkedIn and X.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ladder Capital (LADR) Reports Earnings Tomorrow: What To Expect
Ladder Capital (LADR) Reports Earnings Tomorrow: What To Expect

Yahoo

time24 minutes ago

  • Yahoo

Ladder Capital (LADR) Reports Earnings Tomorrow: What To Expect

Commercial real estate lender Ladder Capital (NYSE:LADR) will be announcing earnings results this Thursday morning. Here's what investors should know. Ladder Capital missed analysts' revenue expectations by 7.1% last quarter, reporting revenues of $51.28 million, down 18.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' tangible book value per share estimates and a significant miss of analysts' EPS estimates. Is Ladder Capital a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Ladder Capital's revenue to decline 21.6% year on year to $56.18 million, a reversal from the 6.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.22 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Ladder Capital has missed Wall Street's revenue estimates twice over the last two years. Looking at Ladder Capital's peers in the thrifts & mortgage finance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. PennyMac Mortgage Investment Trust's revenues decreased 1.4% year on year, missing analysts' expectations by 26.1%, and AGNC Investment reported a revenue decline of 367%, falling short of estimates by 141%. AGNC Investment traded up 1.5% following the results. Read our full analysis of PennyMac Mortgage Investment Trust's results here and AGNC Investment's results here. There has been positive sentiment among investors in the thrifts & mortgage finance segment, with share prices up 8.2% on average over the last month. Ladder Capital is up 2.4% during the same time and is heading into earnings with an average analyst price target of $12.79 (compared to the current share price of $11.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL
A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL

Business Wire

time25 minutes ago

  • Business Wire

A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Share Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. 'We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way. 'This important milestone represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,' commented Erik Lazarich, President of U.S. Operations. Please see link for Full Prescribing Information. About & Milla Pharmaceuticals At our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world. Milla Pharmaceuticals Inc., the U.S. subsidiary of is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.

Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers
Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers

Business Wire

time25 minutes ago

  • Business Wire

Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers

MUNICH--(BUSINESS WIRE)--When BWI Group invented and launched the MagneRide ® magneto‑rheological damper in 2002, the company has propelled MagneRide ® on an extraordinary voyage of technical innovation—an adventure of innovation, challenge and bold breakthroughs. Every generation of MagneRide ® embodies BWI Group's relentless pursuit of sharper vehicle dynamics and superior ride comfort. Constant innovation drives the company to perfect its craft, ensuring that each new iteration delivers a palpably better driving experience. MagneRide ® has elevated vehicle handling and comfort while widening its reach from exotic super‑cars and premium nameplates to a far broader market. First Generation: Started from laboratory magic The story begins in a laboratory brimming with curiosity and ambition. In 2002 the first‑generation MagneRide damper was mass produced for the very first time, endowing the debut application—the Cadillac STS—with unprecedented handling prowess. Second Generation: Reinforced system favoured by super‑cars The second‑generation MagneRide ® damper entered the market in 2006. Upgraded magneto‑rheological fluid and a newly designed piston armed the system for both enhanced comfort and assured control in varied conditions. Europe's top super‑car marques soon extended olive branches, validating MagneRide's unparalleled competitiveness in the high‑performance arena. Third Generation: Leap with speed & passion In 2011, the third‑generation MagneRide ® damper's evolution came with dual‑coil technology pushing response frequency to 1,000 adjustments per second. Meanwhile, dual‑layer sealing made the system more durable, and slashed maintenance costs. Fourth Generation: Benchmark in smart‑drive era Arriving in 2020, the latest generation of MagneRide ® suspension system once again stunned the industry and raised the bar for future mobility. Thanks to a cutting‑edge ECU, wheel‑end accelerometers and an IMU, magneto‑rheological fluid reacts in a lightning‑quick 0.5 millisecond. BWI Group's proprietary algorithmic refinements significantly enhance vehicle stability, ushering in a brand‑new driving paradigm. The latest MagneRide ® suspension system endures more than 300,000 km of gruelling service and operates flawlessly in extremes ranging from −30 °C to 105 °C. It conquers every environment beyond the laboratory, and many flagship models have adopted the system. The fourth generation MagneRide ® suspension system paves the way for boundless possibilities in automotive innovation. From the inaugural invention, through the benchmark‑setting fourth generation, every stride attests to BWI Group's tireless quest for technical excellence and precise understanding of market needs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store